No Detail Found!

Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma

Author(s)
Jianwu Long Department of Hepatobiliary Surgery, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan province, P.R. China, Department of General Surgery, The First Afiliated Hospital of Soochow University. Soochow,Jiangsu province,P.R. China
Longfei Liu Department of Hepatobiliary Surgery, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan province, P.R. China.
Xuefeng Yang Department of Hepatobiliary Surgery, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan province, P.R. China.
Xianzhou Lu Department of General Surgery, Hengyang County People’s Hospital, Hengyang, Hunan province, P.R. China, Department of Hepatobiliary Surgery, The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan province, P.R. China.
Lei Qin Department of General Surgery, The First Afiliated Hospital of Soochow University. Soochow,Jiangsu province,P.R. China
Abstract
Objectives: To investigate the impact of combining lenvatinib with transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC). Methods: This was a retrospective observational study which reviewed the medical records of 103 unresectable HCC patients from January 2017 to June 2020 in The First Afiliated Hospital of Soochow University. It included 46 patients who received TACE plus lenvatinib and 57 patients who received TACE alone. The levels of serum indicators, clinical efect, adverse events, overall survival (OS), and progression-free survival (PFS) were compared between the two groups. Results: AFP and VEGF levels in the TACE+lenvatinib group post-treatment were significantly lower than the TACE group (P0.05), while the two years survival rate in the TACE+lenvatinib group was significantly higher than that in the TACE group (P<0.05). Conclusions: TACE combined with lenvatinib have a high clinical efective rate, with reduced AFP and VEGF levels, higher two year survival rate, and acceptable incidence of adverse events.
Publication Details
Page(s) 1847-1852
Published Journal: Pakistan Journal of Medical Sciences, Volume: 39, Issue: 6, Year: 2023

Request the full text from PASTIC

Keywords
TACE, Lenvatinib, Transcatheter arterial chemoembolization, Unresectable hepatocellular carcinoma
0

Citations

0

Downloads

40

Views